Volume 12, Issue 3 (Vol.12 No.3 Oct 2023)                   rbmb.net 2023, 12(3): 393-402 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ariaee N, Abbasnia S, Sabet F, Mirhossein A, Ahmadi Ghezeldasht S, Moshfegh M, et al . HTLV-1 Proviral Load Absolute RT-qPCR Development for Assessing on Clinical Outcomes in HAM/TSP Patients. rbmb.net 2023; 12 (3) :393-402
URL: http://rbmb.net/article-1-1229-en.html
Immunology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract:   (812 Views)
Background: The significance of HTLV-1 proviral load as a prognostic biomarker in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) has been a subject of controversy. This study aims to assess the impact of HTLV-1 proviral load (PVL) on the clinical outcome in patients with HAM/TSP.

Methods: An absolute quantitative HTLV-1 PVL RT-qPCR, TaqMan method was developed with 100% sensitivity and specificity. Then, from 2005-2018, the HTLV-1 PVL of 90 eligible newly diagnosed HAM/TSP patients were assessed for demographic, clinical symptoms and their associations with HTLV-1-PVL.

Results: The quality control of the designed RT-qPCR showed a sensitivity and specificity of 100%. Spasticity in lower limbs in 58.9% and urinary symptoms in 17.8% of HAM/TSPs were observed. Using this designed RT-qPCR, the HTLV-1-PVL strongly affected spasticity and sphincter disturbance (p=0.05). The multivariate logistic test showed that only the beginning of lower limb weakness along with tremor was associated with PVL (OR: 2.78. 95% CI (0.99-1.02) and p=0.05). Urinary incontinence was prevalent among these patients; however, no association was identified with the HTLV-1 proviral load (PVL).

Conclusion: The absolute RT-qPCR developed for measuring HTLV-1 proviral load (PVL) demonstrated reliable results. Despite a high prevalence of urinary incontinence in these patients, no association was observed with the PVL. Consequently, it appears that HTLV-1 proviral load is specifically associated with developing spasticity in HAM/TSP.
Full-Text [PDF 312 kb]   (443 Downloads)    
Type of Article: Original Article | Subject: Immunology
Received: 2023/08/22 | Accepted: 2023/09/2 | Published: 2024/02/25

References
1. Taylor JM, Nicot C. HTLV-1 and apoptosis: role in cellular transformation and recent advances in therapeutic approaches. Apoptosis. 2008;13(6):733-47. [DOI:10.1007/s10495-008-0208-7] [PMID] []
2. Ahmadi Ghezeldasht S, Shirdel A, Assarehzadegan MA, Hassannia T, Rahimi H, Miri R, Rezaee SA. Human T Lymphotropic Virus Type I (HTLV-I) Oncogenesis: Molecular Aspects of Virus and Host Interactions in Pathogenesis of Adult T cell Leukemia/Lymphoma (ATL). Iran J Basic Med Sci. 2013;16(3):179-95.
3. Yamauchi J, Araya N, Yagishita N, Sato T, Yamano Y. An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers. Pharmacol Ther. 2021;218:107669. [DOI:10.1016/j.pharmthera.2020.107669] [PMID]
4. Trevino A, Aguilera A, Caballero E, Benito R, Parra P, Eiros JM, et al. Trends in the prevalence and distribution of HTLV-1 and HTLV-2 infections in Spain. Virol J. 2012;9:71. [DOI:10.1186/1743-422X-9-71] [PMID] []
5. Barmak K, Harhaj E, Grant C, Alefantis T, Wigdahl B. Human T cell leukemia virus type I-induced disease: pathways to cancer and neurodegeneration. Virology. 2003;308(1):1-12. [DOI:10.1016/S0042-6822(02)00091-0] [PMID]
6. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S, et al. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. JClin Virol: the official publication of the Pan American Society for Clinical Virology. 2011;52(3):172-6. [DOI:10.1016/j.jcv.2011.07.004] [PMID]
7. Yamashiro T, Kamiya H, Miyara T, Gibo S, Ogawa K, Akamine T, et al. CT scans of the chest in carriers of human T-cell lymphotropic virus type 1: presence of interstitial pneumonia. Acad Radiol. 2012;19(8):952-7. [DOI:10.1016/j.acra.2012.03.020] [PMID]
8. Mirhosseini A, Mohareri M, Arab R, Rezaee SA, Shirdel A, Koshyar MM, et al. Complete sequence of human T cell leukemia virus type 1 in ATLL patients from Northeast Iran, Mashhad revealed a prematurely terminated protease and an elongated pX open reading frame III. Infect Genet Evol. 2019;73:460-9. [DOI:10.1016/j.meegid.2019.05.012] [PMID]
9. Pashabayg CR, Momenifar N, Malekpour SA, Sadeghi M, Foroushani AR, Rafatpanah H, et al. Phylogenetic and phylodynamic study of Human T-cell lymphotropic virus Type 1 (HTLV-1) in Iran. Infect Genet Evo. 2020;85:104426. [DOI:10.1016/j.meegid.2020.104426] [PMID]
10. Shibasaki H, Endo C, Kuroda Y, Kakigi R, Oda K, Komine S. Clinical picture of HTLV-I associated myelopathy. J Neurol Sci. 1988;87(1):15-24. [DOI:10.1016/0022-510X(88)90050-0] [PMID]
11. Izumo S, Goto I, Itoyama Y, Okajima T, Watanabe S, Kuroda Y, et al. Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology. 1996;46(4):1016-21. [DOI:10.1212/WNL.46.4.1016] [PMID]
12. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005;24(39):6058-68. [DOI:10.1038/sj.onc.1208968] [PMID]
13. Kubota R, Hanada K, Furukawa Y, Arimura K, Osame M, Gojobori T, Izumo S. Genetic stability of human T lymphotropic virus type I despite antiviral pressures by CTLs. J Immunol (Baltimore, Md : 1950). 2007;178(9):5966-72. [DOI:10.4049/jimmunol.178.9.5966] [PMID]
14. Yamano Y, Sato T. Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis. Front Microbiol. 2012;3:389. [DOI:10.3389/fmicb.2012.00389] [PMID] []
15. Demontis MA, Hilburn S, Taylor GP. Human T cell lymphotropic virus type 1 viral load variability and long-term trends in asymptomatic carriers and in patients with human T cell lymphotropic virus type 1-related diseases. AIDS Res Hum Retroviruses. 2013;29(2):359-64. [DOI:10.1089/aid.2012.0132] [PMID]
16. Martins ML, Guimaraes JC, Ribas JG, Romanelli LC, de Freitas Carneiro-Proietti AB. Long-term follow-up of HTLV-1 proviral load in asymptomatic carriers and in incident cases of HAM/TSP: what is its relevance as a prognostic marker for neurologic disease? J Neurovirol. 2017;23(1):125-33. [DOI:10.1007/s13365-016-0484-x] [PMID]
17. Takenouchi N, Yamano Y, Usuku K, Osame M, Izumo S. Usefulness of proviral load measurement for monitoring of disease activity in individual patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol. 2003;9(1):29-35. [DOI:10.1080/13550280390173418] [PMID]
18. Osame M, Janssen R, Kubota H, Nishitani H, Igata A, Nagataki S, et al. Nationwide survey of HTLV‐I-associated myelopathy in Japan: Association with blood transfusion. Ann Neurol. 1990;28(1):50-6. [DOI:10.1002/ana.410280110] [PMID]
19. Nakagawa M, Izumo S, Ijichi S, Kubota H, Arimura K, Kawabata M, Osame M. HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J Neurovirol. 1995;1(1):50-61. [DOI:10.3109/13550289509111010] [PMID]
20. Rafatpanah H, Rezaee A, Etemadi MM, Hosseini RF, Khorram B, Afsahr L, et al. The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran. J Neuroimmunol. 2012;250(1-2):87-93. [DOI:10.1016/j.jneuroim.2012.05.004] [PMID]
21. Kulkarni A, Bangham CR. HTLV-1: regulating the balance between proviral latency and reactivation. Front Microbiol. 2018;9:449. [DOI:10.3389/fmicb.2018.00449] [PMID] []
22. Nozuma S, Kubota R, Jacobson S. Human T-lymphotropic virus type 1 (HTLV-1) and cellular immune response in HTLV-1-associated myelopathy/tropical spastic paraparesis. J Neurovirol. 2020:1-12. [DOI:10.1007/s13365-020-00881-w] [PMID] []
23. Ghezeldasht SA, Sadeghian H, Azarpazhooh MR, Shamsian SAA, Rafatpanah H, Mahmoodi M, Rezaee SA. Evaluation of T Regulatory Lymphocytes Transcription Factors in HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Patients. Appl Biochem Biotechnol. 2017;182(4):1403-14. [DOI:10.1007/s12010-017-2406-7] [PMID]
24. Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol. 1998;4(6):586-93. [DOI:10.3109/13550289809114225] [PMID]
25. Saito M. Immunogenetics and the Pathological Mechanisms of Human T-Cell Leukemia VirusType 1- (HTLV-1-)Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). Interdiscip Perspect Infect Dis. 2010;2010:478461. [DOI:10.1155/2010/478461] [PMID] []
26. Lezin A, Olindo S, Oliere S, Varrin-Doyer M, Marlin R, Cabre P, et al. Human T lymphotropic virus type I (HTLV-I) proviral load in cerebrospinal fluid: a new criterion for the diagnosis of HTLV-I-associated myelopathy/tropical spastic paraparesis? J Infect Dis. 2005;191(11):1830-4. [DOI:10.1086/429962] [PMID]
27. Grassi MF, Olavarria VN, Kruschewsky Rde A, Mascarenhas RE, Dourado I, Correia LC, et al. Human T cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP. J Med Virol. 2011;83(7):1269-74. [DOI:10.1002/jmv.22087] [PMID]
28. Furtado Mdos S1 AR, Romanelli LC, Ribeiro MA, Ribas JG, Torres EB, Barbosa-Stancioli EF, Proietti AB, Martins ML. Monitoring the HTLV-1 proviral load in the peripheral blood of asymptomatic carriers and patients with HTLV-associated myelopathy/tropical spastic paraparesis from a Brazilian cohort: ROC curve analysis to establish the threshold for risk disease. J Med Virol. 2012 84(4):664-71. [DOI:10.1002/jmv.23227] [PMID]
29. Champs AP, Passos VM, Barreto SM, Vaz LS, Ribas JG. [HTLV-1 associated myelopathy: clinical and epidemiological profile in a 10-year case series study]. Rev Soc Bras Med Trop. 2010;43(6):668-72. [DOI:10.1590/S0037-86822010000600013] [PMID]
30. Lima MA, Harab RC, Schor D, Andrada-Serpa MJ, Araujo AQ. Subacute progression of human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol. 2007;13(5):468-73. [DOI:10.1080/13550280701510096] [PMID]
31. Poetker SK, Porto AF, Giozza SP, Muniz AL, Caskey MF, Carvalho EM, Glesby MJ. Clinical manifestations in individuals with recent diagnosis of HTLV type I infection. J Clin Virol: the official publication of the Pan American Society for Clinical Virology. 2011;51(1):54-8. [DOI:10.1016/j.jcv.2011.02.004] [PMID] []
32. Vakili R, Sabet F, Aahmadi S, Boostani R, Rafatpanah H, Shamsian A, Rezaee SA. Human T-lymphotropic Virus Type I (HTLV-I) Proviral Load and Clinical Features in Iranian HAM/TSP Patients: Comparison of HTLV-I Proviral Load in HAM/TSP Patients. Iran J Basic Med Sci. 2013;16(3):268-72.
33. Oliveira P, Castro NM, Carvalho EM. Urinary and sexual manifestations of patients infected by HTLV-I. Clinics (Sao Paulo). 2007;62(2):191-6. [DOI:10.1590/S1807-59322007000200015] [PMID]
34. Dourado I, Alcantara LC, Barreto ML, da Gloria Teixeira M, Galvao-Castro B. HTLV-I in the general population of Salvador, Brazil: a city with African ethnic and sociodemographic characteristics. J Acquir Immune Defic Syndr. 2003;34(5):527-31. [DOI:10.1097/00126334-200312150-00013] [PMID]
35. Sanchez-Palacios C, Gotuzzo E, Vandamme AM, Maldonado Y. Seroprevalence and risk factors for human T-cell lymphotropic virus (HTLV-I) infection among ethnically and geographically diverse Peruvian women. Int J Infect Dis. 2003;7(2):132-7. [DOI:10.1016/S1201-9712(03)90009-9] [PMID]
36. Castillo JL, Cea JG, Verdugo RJ, Cartier L. Sensory dysfunction in HTLV-I-associated myelopathy/tropical spastic paraparesis. A comprehensive neurophysiological study. Eur Neurol. 1999;42(1):17-22. [DOI:10.1159/000008063] [PMID]
37. Bhigjee AI, Kelbe C, Haribhai HC, Windsor IM, Hoffmann MH, Modi G, et al. Myelopathy associated with human T cell lymphotropic virus type I (HTLV-I) in natal, South Africa. A clinical and investigative study in 24 patients. Brain. 1990;113 ( Pt 5):1307-20. [DOI:10.1093/brain/113.5.1307] [PMID]
38. Vernant JC, Maurs L, Gessain A, Barin F, Gout O, Delaporte JM, et al. Endemic tropical spastic paraparesis associated with human T-lymphotropic virus type I: a clinical and seroepidemiological study of 25 cases. Ann Neurol. 1987;21(2):123-30. [DOI:10.1002/ana.410210204] [PMID]
39. Matsuzaki T, Nakagawa M, Nagai M, Usuku K, Higuchi I, Arimura K, et al. HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years. J Neurovirol. 2001;7(3):228-34. [DOI:10.1080/13550280152403272] [PMID]
40. Boostani R, Vakili R, Hosseiny SS, Shoeibi A, Fazeli B, Etemadi MM, et al. Triple therapy with prednisolone, pegylated interferon and sodium valproate improves clinical outcome and reduces human T-cell leukemia virus type 1 (HTLV-1) proviral load, tax and HBZ mRNA expression in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. Neurotherapeutics. 2015;12(4):887-95. [DOI:10.1007/s13311-015-0369-3] [PMID] []

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb